Health · 5 views
Tumor markers reveal which HER2+ breast cancer patients may respond to less intensive chemotherapy
The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249).
Summary
The Journal of Clinical Oncology has published secondary results from the ECOG-ACRIN Cancer Research Group's CompassHER2-pCR clinical trial (EA1181, NCT04266249). The findings help identify which early-stage HER2-positive (HER2+) breast cancers may be most likely to respond to less intensive chemotherapy than the current standard. Patients with early-stage HER2+ breast cancer usually receive multiagent chemotherapy with anti-HER2 drugs before surgery.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Pausing certain arthritis drugs after COVID-19 vaccination raises flare risk without improving antibody responseContinue reading
- CDC funding for HIV prevention shifted from providers to states under TrumpContinue reading
- HIV treatment has transformed lives in the UK, but stigma lingersContinue reading
- Early-onset menopause linked to increased symptoms of anxiety and depressionContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow